Table 2.
Latency in seconds in behavioral alterations after EEOS administration at different doses for the evaluation of myorelaxation.
| Doses (mg/kg) | Decreased Motility | Myorelaxation | Deep and rhythmic breathing | Somnolence | Respiratory depression (ACB*) | Transient loss of posture reflex | Return |
|---|---|---|---|---|---|---|---|
| 200 | 365.7 ± 27.59 | 413.7 ± 18.30 | 454.6 ± 11.52 | 501.6 ± 11.30 | 788.6 ± 90.58 | – | 3047 ± 306.1 |
| 300 | 218.4 ± 15.27 | 275.2 ± 10.59 | 312.1 ± 24.76 | 344.0 ± 23.93 | 645.0 ± 50.56 | 842.1 ± 46.39 | 4404 ± 276.0 |
| 400 | 133.0 ± 16.01 | 151.0 ± 15.94 | 176.9 ± 11.85 | 209.4 ± 20.20 | 253.9 ± 19.13 | 384.1 ± 34.70 | 8596 ± 600.2 |
| DZP (5 mg/kg i.p.) | 54.89 ± 11.16 | 104.9 ± 11.69 | – | 170.6 ± 11.42 | 333.3 ± 17.11 | 398.9 ± 16.30 | 10,959 ± 193.9 |
*
ACB: Abdominal-costal breathing.